Efficacy and Safety of NOACs Compared With VKAs for Patients With Atrial Fibrillation After Transcatheter Aortic Valve Implantation: A System Review and Meta-Analysis

Junye Ge, MD\(^1\), Wenqiang Han, MD, PhD\(^1\), Chuanzhen Ma, MD\(^1\), Kellina Maduray, MD\(^1\)\(^\ddagger\), Tongshuai Chen, MD, PhD\(^1\), and Jingquan Zhong, MD, PhD, FACC\(^1,2\)

Abstract
Novel oral anticoagulants (NOACs) are preferentially recommended in patients with nonvalvular atrial fibrillation (AF) for stroke prevention over vitamin K antagonists (VKAs). However, the evidence regarding the efficacy and safety of NOACs versus VKAs after transcatheter aortic valve implantation (TAVI) in patients with AF is very rare. Pubmed, Embase, Web of science, and Cochrane Databases were searched for eligible studies published before May 19, 2022. A total of 11 studies were included in this meta-analysis involving 27,107 patients. Regarding primary outcomes, there were no differences between NOACs and VKAs in all-cause mortality (RR: 0.84, 95% CI: (0.69, 1.02)) and stroke (RR: 1.00, 95% CI: (0.85, 1.19)). With respect to secondary outcomes, NOACs were associated with reduced incidence of bleeding (RR: 0.77, 95% CI: (0.71, 0.83)) and intracranial bleeding (RR: 0.57, 95% CI: (0.39, 0.83)), whereas no significant differences were found in major or life-threatening bleeding (RR: 0.98, 95% CI: (0.82, 1.17)) and myocardial infarction (RR: 1.37, 95% CI: (0.83, 2.26)). Our meta-analysis revealed the safety and efficacy of NOACs may be superior to VKAs in AF patients undergoing TAVI.

Keywords
transcatheter aortic valve implantation, atrial fibrillation, anticoagulant, novel oral anticoagulant, vitamin K antagonist

Introduction
Transcatheter aortic valve implantation (TAVI) has become the preferred strategy for the treatment of symptomatic severe aortic stenosis in older adults, with indications broadened to include intermediate or low-risk patients.\(^1,2\) Atrial fibrillation (AF) is one of the most common persistent arrhythmias, with an annually increasing incidence, which is known to be closely associated with aortic stenosis.\(^3,5\) The prevalence of previous AF is as high as 51.1% among patients undergoing TAVI, whereas the new-onset AF rate ranges from 1% to 32%, increasing the risk of thromboembolic and bleeding events.\(^5,6\) The
majority of AF patients require oral anticoagulants (OACs), such as vitamin K antagonists (VKAs) or novel oral anticoagulants (NOACs), on a long-term basis to reduce thromboembolic events. Due to their superior efficacy and safety, NOACs has been widely used in clinical practice, which has become the preferred choice for stroke prevention in patients with nonvalvular AF.\textsuperscript{7,8}

Currently, evidence regarding the efficacy and safety of NOACs versus VKAs after TAVI in patients with AF is very rare, thereby under debate. Throughout the available clinical evidence, the results were also controversial. A multicenter European study enrolled 962 patients undergoing TAVI, more than 99% of whom suffered from AF.\textsuperscript{9} The findings revealed that the composite outcomes, including any cerebrovascular event, all-cause mortality, and myocardial infarction, were significantly higher in NOACs than in VKAs during 1-year follow-up. In contrast, the largest observational study, including 21,131 AF patients from America, compared the clinical outcomes of NOACs versus VKAs after TAVI.\textsuperscript{10} The results demonstrated that the AF patients prescribed NOACs experienced lesser bleeding, intracranial hemorrhage or death events with comparable stroke events after TAVI during 1-year follow-up. On the one hand, some studies proved that NOACs were inferior to VKAs with increased composite outcomes or major bleeding events\textsuperscript{9,11}; on the other hand, others supported that NOACs were equivalent or superior to VKAs in all-cause mortality, stroke, bleeding, and so on for patients with AF after TAVI.\textsuperscript{10,12,13} Due to the large difference in results, we analyzed the available clinical studies\textsuperscript{9-19} data to systematically evaluate the efficacy and safety of NOACs versus VKAs after TAVI in patients with AF to provide a reference for clinical treatment.

\section*{Methods}

This meta-analysis was performed on the basis of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.\textsuperscript{20} A review protocol was not registered for this meta-analysis.

\section*{Search Strategy}

Pubmed, Embase, Web of science, and Cochrane Databases were fully searched for eligible studies published before May 19, 2022. The detailed search strategy is summarized in Table 1 in the online supplementary materials.

\section*{Study Selection and Quality Assessment}

The inclusion criteria: (1) The subjects were TAVI recipients with AF (AF patients >90\% of the total subjects). (2) The study included comparisons between NOACs and VKAs groups. The exclusion criteria: (1) No-AF patients or AF patients <90\% of the total subjects. (2) Studies that failed to report relevant data regarding NOACs and VKAs groups. The study quality was independently assessed by two authors based on the Newcastle-Ottawa Scale\textsuperscript{21} (observational study) or Cochrane Collaboration Risk of Bias Tool\textsuperscript{22} (randomized controlled trial). Any inconsistencies were determined after discussion by two authors.

\section*{Data Extraction and Summary Outcomes}

The required data were independently extracted by the two authors, including first author’s name, year, country, male proportion, number of patients, CHA2DS2-VASc score, HAS-BLED score, duration of follow-up, specific outcome values and so on. All-cause mortality and stroke (new-onset stroke) were evaluated as primary outcomes. Secondary outcomes included bleeding, major or life-threatening bleeding, intracranial bleeding and myocardial infarction. The events and total counts between the NOACs and VKAs group as well as the relative risks (RRs) with 95\% confidence intervals (CIs) were extracted or computed.

\section*{Statistical Analysis}

The effect size was expressed as RRs with 95\% CIs. The heterogeneity among studies was assessed by the Q test. $\hat{I}^2 \geq 50\%$ was regarded as high heterogeneity, while $\hat{I}^2 < 50\%$ indicated low heterogeneity. If $\hat{I}^2 \geq 50\%$, the random effect model was used. Otherwise, the fixed effect model was applied for meta-analysis. The high heterogeneity among the studies was further analyzed by the Galbraith star chart. Univariate meta-regression was performed to explore the influencing factors of heterogeneity. Sensitivity analysis was performed to assess the stability of the findings. Publication bias was evaluated by Egger’s test. A $P < .05$ was considered statistically significant in all analyses. The software Stata version 15.1 was used in this meta-analysis.

\section*{Results}

\section*{Study Selection and Quality Assessment}

The detailed literature search is shown in Figure 1. A total of 2070 pieces of literature were initially retrieved. One randomized controlled trial and 10 observational studies were finally included in this meta-analysis after multiple screenings. A high quality was achieved for the randomized controlled trial by Cochrane Collaboration Risk of Bias Tool (Figure 1 in the online supplementary materials). Based on the Newcastle-Ottawa scale, the scores of the included observational studies ranged from 5 to 9, indicating that the studies achieved moderate to high quality (Table 2 in the online supplementary materials).

\section*{Study Characteristics}

The baseline characteristics of the included studies are listed in Table 1. Most of the studies have been published in the last five years from multiple countries. This meta-analysis included 27,107 patients. Only one study included more than 10,000 patients, while the other studies had less than 2000 patients.
The studies also differed greatly in the percentage of male participants and the number of patients enrolled. The majority of patients receiving TAVI were over 80 years old, among whom hypertension was prevalent. In terms of the overall patients, a higher CHA2DS2-VASc score was observed, indicating a higher risk of thromboembolic events.

### Summary Outcomes

**Primary outcomes.** All-cause mortality data were available from 10 studies (Figure 2A). The results showed that the all-cause mortality in the NOACs group was lower than that in the VKAs group, but there was no significant difference ($RR: 0.84, 95\% CI: (0.69, 1.02)$). High heterogeneity was observed ($I^2 = 61.6\%, P = .005$).

Stroke data from nine studies were analyzed (Figure 2B). Meta-analysis showed comparable stroke rates between the NOACs and VKAs group with no significant difference ($RR: 1.00, 95\% CI: (0.85, 1.19)$). There was no heterogeneity across studies ($I^2 = 0.0\%, P = .607$).

**Secondary outcomes.** Bleeding data were reported in eight studies (Figure 3A). It was found that bleeding events were less frequent in the NOACs group than in the VKAs group ($RR: 0.77, 95\% CI: (0.71, 0.83)$). Low heterogeneity was observed ($I^2 = 44.8\%, P = .080$).

Seven studies provided data on major or life-threatening bleeding (Figure 3B). There were similar event rates in the NOACs group compared to VKAs group ($RR: 0.98, 95\% CI: (0.82, 1.17)$). There was low heterogeneity across studies ($I^2 = 30.6\%, P = .194$).

Data from five studies were evaluated regarding intracranial bleeding (Figure 3C). The NOACs group had a significantly lower rate of intracranial bleeding compared with the VKAs group ($RR: 0.57, 95\% CI: (0.39, 0.83)$). Low heterogeneity was observed ($I^2 = 3.6\%, P = .386$).

Four studies published data on myocardial infarction (Figure 3D). The meta-analysis showed no significant difference in myocardial infarction between the NOACs and VKAs groups with a trend toward increased events in the NOACs group ($RR: 1.37, 95\% CI: (0.83, 2.26)$). There was no heterogeneity across studies ($I^2 = 0.0\%, P = .781$).

### Heterogeneity Analysis

Given the high heterogeneity observed with all-cause mortality, we explored the sources of heterogeneity qualitatively and...
Table 1. Baseline Characteristics of the Included Studies.

| Author          | Year | Country        | Total Population | Number (NOAC) | Number (VKA) | NOAC Species | Age (mean) | Male (%) | CHADS2-VASc (mean) | HAS-BLED | Follow-up | Hypertension (%) | Diabetes (%) | Antiplatelet Therapy |
|-----------------|------|----------------|------------------|---------------|--------------|--------------|------------|----------|------------------|-----------|------------|------------------|--------------|----------------------|
| Seeger          | 2017 | Germany        | 272              | 141           | 131          | Apixaban     | 81.3       | 50.7     | 4.9              | 3.1       | 12 months | -                | 32.4         | -                    |
| Airaes          | 2017 | American       | 170              | 58            | 112          | -            | -          | -        | -                | -         | 1 year    | -                | -            | -                    |
| Geis            | 2018 | Germany        | 326              | 154           | 172          | Multiple     | 83.1       | 47.2     | 4.7              | 2.8       | 6 months  | 93.6             | 31.9         | None                  |
| Mangner         | 2018 | Germany        | 598              | 182           | 416          | Multiple     | 80 (median) | 43.8     | 5.5              | 3         | 12 months | 97               | 48.2         | -                    |
| Jochheim        | 2019 | Multinational  | 962              | 326           | 636          | Multiple     | 81.3       | 47.5     | ≥2               | -         | 1 year    | 89.6             | 32.3         | None, single or dual |
| Butt            | 2019 | Denmark        | 735              | 219           | 516          | Multiple     | 82 (median) | 53.7     | 4.9              | 3.3       | 369 days  | 88.2             | 22.3         | None, single or dual |
| Kosmidou        | 2019 | Multinational  | 933              | 155           | 778          | -            | 82.8       | 65.6     | 5.6              | -         | 2.8 years | 91.7             | 35.3         | -                    |
| Okoh            | 2019 | American       | 151              | 31            | 121          | Rivaroxaban  | -          | -        | -                | -         | 36 months | -                | -            | -                    |
| Kawahima        | 2020 | Japan          | 403              | 227           | 176          | Multiple     | 84.4       | 33.3     | 5.1              | 2.7       | 568 days  | 76.2             | 24.3         | None, single or dual |
| Tanawuttiwat    | 2022 | American       | 21131            | 8127          | 13004        | Multiple     | 83         | 56.7     | 3                | -         | 1 year    | 91.7             | 36.9         | -                    |
| Van Mieghem     | 2021 | Multinational  | 1426             | 713           | 713          | Edoxaban     | 82.1       | 52.5     | 4.5              | -         | 530 days  | 91.4             | 37.0         | None, single or dual |

Note: NOAC = New Oral Anticoagulant, VKA = Vitamin K Antagonist, CHADS2-VASc = Congestive Heart Failure, Hypertension, Atrial Fibrillation, Diabetes, Age, Stroke, Vascular Disease, and Age; HAS-BLED = Hemorrhage, Age, Stroke, Hypertension, Abnormal Renal/Liver Function, Bleeding, Drugs Alcohol.
quantitatively by using the Galbraith star chart and meta-regression. As seen in the Galbraith star chart (Figure 2 in the online supplementary materials), the high heterogeneity may be related to the studies including Jochheim et al, Mangner et al, and Kawashima et al studies. After excluding these studies, meta-analysis (Figure 3 in the online supplementary materials) showed a significant reduction in heterogeneity ($I^2 = 14.9\%$, $P = .316$) and change in result ($RR: 0.85, 95\% CI: (0.80, 0.91)$). The univariate meta-regression analysis did not find the possible source of heterogeneity, for instance total population, age, male, hypertension, diabetes, follow-up, and CHA2DS2-VASc (Table 3 in the online supplementary materials).

Figure 2. Forest plot to compare NOACs with VKAs in primary outcomes including all-cause mortality (A) and stroke (B).
Figure 3. Forest plot to compare NOACs with VKAs in secondary outcomes including bleeding (A), major or life-threatening bleeding (B), intracranial bleeding (C) and myocardial infarction (D).
Sensitivity Analysis

Sensitivity analysis performed on all-cause mortality, bleeding and intracranial bleeding revealed a significant change in observed results (Figure 4A-C in the online supplementary materials). For all-cause mortality, the result was statistically significant after excluding Jochheim et al study (RR: 0.79, 95% CI: (0.65, 0.95)) or Seeger et al study (RR: 0.81, 95% CI: (0.67, 0.98)). Based on the exclusion of Tanawuttiwat et al study, no significant differences were found between NOACs and VKAs in bleeding (RR: 0.89, 95% CI: (0.77, 1.03)) and intracranial bleeding (RR: 0.71, 95% CI: (0.39, 1.29)). In the remaining outcomes, the results did not change significantly following the sensitivity analysis (Figure 4D-F in the online supplementary materials).

Bias Assessment

No publication bias was observed by Egger’s test in all-cause mortality ($P = .895$), stroke ($P = .701$), bleeding ($P = .226$), and major or life-threatening bleeding ($P = .428$). Due to the small number of included studies, publication bias was not evaluated in other outcomes.

Discussion

This meta-analysis comprised all studies reporting AF patients undergoing TAVI and studies with AF patients accounting for more than 90% of all TAVI patients, so as to minimize the impact of other disorders with anticoagulation-related indications while ensuring sufficient number of studies. Regarding the primary outcomes, NOACs had no significant difference from VKAs in terms of all-cause mortality and stroke. With respect to secondary outcomes, NOACs were associated with a reduced incidence of events in bleeding and intracranial bleeding, whereas no significant differences were found between NOACs and VKAs for major or life-threatening bleeding and myocardial infarction.

The anticoagulant regimen after TAVI is complex. Low-dose aspirin is usually used to prevent valve thrombosis in TAVI patients without anticoagulant indications. The administration of antithrombotic regimens in TAVI patients with anticoagulant indications remains complex and controversial. The reason for added antiplatelet therapy in addition to anticoagulation may be to reduce periprocedural thromboembolic events during valve endolethialization in AF patients after TAVI. In the Popular-TAVI trial, Cohort B confirmed that anticoagulants alone were associated with fewer major bleeding events compared with anticoagulants plus clopidogrel after TAVI in patients with anticoagulant indications, with comparable incidence of stroke, myocardial infarction, or all-cause death events. A multicenter observational study has come to a similar conclusion that warfarin plus antiplatelet agents increased the risk of major bleeding after TAVI in AF patients, and failed to reduce stroke or adverse cardiovascular events occurrence, compared with warfarin alone. Based on this, guidelines and expert consensus recommend long-term anticoagulation in patients with anticoagulant indications after TAVI, and OACs alone is preferred.

Multiple randomized controlled trials indicated that NOACs reduced the incidence of stroke/transient ischemic attack and the risk of major bleeding compared to VKAs in patients with nonvalvular AF, which has been recommended by guidelines for the management of AF. However, whether VKAs or NOACs are the preferred anticoagulant therapy for patients with AF undergoing TAVI is still unknown. The 2020 ACC/AHA Guideline indicated that NOACs can be used as an alternative to VKAs after 3 months of biologic valve replacement in patients with AF. The ENVISAGE-TAVI AF trial included 1426 AF patients undergoing TAVI to compare the efficacy and safety of edoxaban versus VKAs. The results confirmed that edoxaban was noninferior to VKAs in terms of composite adverse clinical events; however, the patients treated with edoxaban had a higher incidence of major bleeding, mainly major gastrointestinal bleeding. The ATLANTIS trial demonstrated the use of apixaban after TAVI was not superior to the standard antithrombotic therapy in patients with or without anticoagulation indication, based on the net clinical benefit. In the subgroup analysis of apixaban versus VKAs, AF patients accounted for less than 90% of TAVI patients, so the trial was not included in our meta-analysis. To date, the latest guidelines do not specify the preference of NOACs or VKAs for anticoagulant therapy in AF patients after TAVI.

Although the meta-analyses on the clinical outcomes of NOACs versus VKAs after TAVI in patients with AF have been published, the search was more comprehensive with an increase in the number of patients enrolled and only studies with AF patients accounting for more than 90% of all TAVI patients were included in our meta-analysis. Most importantly, the results of our meta-analysis differed from those meta-analyses. A meta-analysis found that NOACs had lower risks of all-cause mortality and bleeding than VKAs at 1 year after TAVI in AF patients. Another meta-analysis conducted by Memon et al showed no significant difference in stroke or systemic embolism, all-cause mortality, major bleeding, intracranial hemorrhage, and myocardial infarction between NOACs versus VKAs for AF patients undergoing TAVI. Our meta-analysis revealed that the patients prescribed NOACs had a lower incidence of bleeding and intracranial bleeding. However, sensitivity analyses found that the effects of NOACs and VKAs were equivalent in bleeding and intracranial bleeding after the exclusion of Tanawuttiwat et al study. The largest observational study by Tanawuttiwat et al was not included in prior meta-analysis. Interestingly, the patients prescribed NOACs tended to have a lower incidence of all-cause mortality with the $RR$s less than 1 despite no statistical difference. Qualitative analysis showed that the three studies might be the source of the large heterogeneity of all-cause mortality, yet meta-regression did not find the specific factors leading to heterogeneity. Considering the existing clinical studies and meta-analyses, the safety and efficacy of NOACs were not inferior to VKAs in AF patients undergoing TAVI. Moreover, due
to the inherent disadvantages of VKAs, such as the narrow therapeutic window, high compliance and food interactions, NOACs are more popular among clinicians. Our meta-analysis demonstrated that NOACs were a feasible alternative for VKAs in AF patients after TAVI, which may benefit clinical decision-making.

Limitations
Our meta-analysis is subject to several limitations. The type of NOACs differed among the included studies. NOACs were not subdivided explicitly according to the type. The combined antiplatelet regimens varied greatly among different studies. The aforementioned factors may be a potential source of heterogeneity. All-cause mortality analysis revealed significant heterogeneity, and the results for bleeding and intracranial bleeding were less stable. As a result, caution must be exercised when interpreting these findings.

Conclusions
Our meta-analysis revealed the safety and efficacy of NOACs may be superior to VKAs in AF patients undergoing TAVI. Therefore, NOACs may be a viable alternative for VKAs after TAVI in AF patients, which may aid clinical decision-making.

Author Contributions
JG designed the study, selected literature, collected and analyzed data, and drafted the manuscript. WH, CM, and KM selected literature and collected and analyzed data. TC and JZ analyzed data and reviewed the manuscript. All authors contributed to the manuscript revision and approved the submitted version.

Data Availability
All relevant data are presented in the review and supplemental material.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethics Approval and Consent to Participate
Our institution did not require informed consent or ethical approval from the patients for reporting a systematic review and meta-analysis.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by the Qingdao Key Health Discipline Development Fund; and National Natural Science Foundation of China (82270331).

ORCID iDs
Kellina Maduray  https://orcid.org/0000-0001-9038-5212
Jingquan Zhong  https://orcid.org/0000-0001-9547-4070

Supplemental Material
Supplemental material for this article is available online.

References
1. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022;43(7):561-632.
2. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: Executive summary: A report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2021;143(5):e35-e71.
3. Morin DP, Bernard ML, Madias C, Rogers PA, Thihalolipavan S, Estes NA. 3rd. The state of the art: Atrial fibrillation epidemiology, prevention, and treatment. Mayo Clin Proc. 2016;91(12):1778-1810.
4. Chugh SS, Havmoeller R, Narayan K, et al. Worldwide epidemiology of atrial fibrillation: A global burden of disease 2010 study. Circulation. 2014;129(8):837-847.
5. Tarantini G, Mojoli M, Urena M, Vahanian A. Atrial fibrillation in patients undergoing transcatheter aortic valve implantation: Epidemiology, timing, predictors, and outcome. Eur Heart J. 2017;38(17):1285-1293.
6. Mojoli M, Gersh BJ, Barioli A, et al. Impact of atrial fibrillation on outcomes of patients treated by transcatheter aortic valve implantation: A systematic review and meta-analysis. Am Heart J. 2017;192:64-75.
7. Chen ST, Patel MR. Comparison of anticoagulant therapy for atrial fibrillation - novel oral anticoagulants versus vitamin K antagonists. Prog Cardiovasc Dis. 2018;60(4-5):514-523.
8. Hindricks G, Potpara T, Dages N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498.
9. Jochheim D, Barbanti M, Capretti G, et al. Oral anticoagulant type and outcomes after transcatheter aortic valve replacement. JACC Cardiovasc Inter. 2019;12(16):1566-1576.
10. Tanawuttiwat T, Stebbins A, Marquis-Gravel G, Vemulapalli S, Kosinski AS, Cheng A. Use of direct oral anticoagulant and outcomes in patients with atrial fibrillation after transcatheter aortic valve replacement: Insights from the STS/ACC TVT registry. J Am Heart Assoc. 2022;11(1):e023561.
11. Van Mieghem NM, Unverdorben M, Hengstenberg C, et al. Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR. N Engl J Med. 2021;385(23):2150-2160.
12. Seeger J, Gonska B, Rodewald C, Rottbauer W, Wöhrl J. Apixaban in patients with atrial fibrillation after transfemoral aortic valve replacement. JACC Cardiovasc Interv. 2017;10(1):66-74.
13. Kawashima H, Watanabe Y, Hioki H, et al. Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation.
fibrillation after TAVR. JACC Cardiovasc Interv. 2020;13(22):2587-2597.
14. Butt JH, De Backer O, Olesen JB, et al. Vitamin K antagonists vs. Direct oral anticoagulants after transcatheter aortic valve implantation in atrial fibrillation. Eur Heart J Cardiovasc Pharmacother. 2021;7(1):11-19.
15. Geis NA, Kiriakou C, Chorianopoulos E, Uhlmann L, Katus HA, Bekeredjian R. NOAC Monotherapy in patients with concomitant indications for oral anticoagulation undergoing transcatheter aortic valve implantation. Clin Res Cardiol. 2018;107(9):799-806.
16. Kosmidou I, Liu Y, Alu MC, et al. Antithrombotic therapy and cardiovascular outcomes after transcatheter aortic valve replacement in patients with atrial fibrillation. JACC Cardiovasc Interv. 2019;12(16):1580-1589.
17. Mangner N, Crusius L, Haussig S, et al. Continued versus interrupted oral anticoagulation during transfemoral transcatheter aortic valve implantation and impact of postoperative anticoagulant management on outcome in patients with atrial fibrillation. Am J Cardiol. 2019;123(7):1134-1141.
18. Alraiès MC, Pacha HM, Buchanan K, et al. TCT-786 Antithrombotic management for atrial fibrillation patient undergoing transcatheter aortic valve replacement. J Am Coll Cardiol. 2017;70(18):B115-B116.
19. Okoh AK, Singh S, Khakwani Z, Chen C, Russo M, Cohen M. CRT-600.16 rivaroxaban vs warfarin for stroke prevention in patients with atrial fibrillation undergoing transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2020;13(16):1580-1589.
20. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Br Med J. 2021;372:n71.
21. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603-605.
22. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. Br Med J. 2011;343:d5928.
23. Rodés-Cabau J, Dauerman HL, Cohen MG, et al. Antithrombotic treatment in transcatheter aortic valve implantation: Insights for cerebrovascular and bleeding events. J Am Coll Cardiol. 2013;62(25):2349-2359.
24. Nijenhuis VJ, Brouwer J, Delewi R, et al. Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J Med. 2020;382(18):1696-1707.
25. Abdul-Jawad Altisent O, Durand E, Munoz-Garcia AJ, et al. Warfarin and antiplatelet therapy versus warfarin alone for treating patients with atrial fibrillation undergoing transcather aortic valve replacement. JACC Cardiovasc Interv. 2016;9(16):1706-1717.
26. Ten Berg J, Sibbing D, Rocca B, et al. Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: A consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease. Eur Heart J. 2021;42(23):2265-2269.
27. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-2104.
28. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-891.
29. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992.
30. Connolly SJ, Ezekowitz MD, Yusuf S, et al. dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151.
31. Collet JP, Van Belle E, Thiele H, et al. Apixaban vs. Standard of care after transcatheter aortic valve implantation: The ATLANTIS trial. Eur Heart J. 2022;43(29):2783-2797.
32. Memon MM, Siddiqui AA, Amin E, et al. Novel oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation after transcatheter aortic valve replacement: A systematic review and meta-analysis. Catheter Cardiovasc Interv. 2022;99(7):2101-2110.
33. Ooi AJQ, Wong C, Tan TWE, et al. A systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulants vs vitamin K antagonists after transcatheter aortic valve replacement in patients with atrial fibrillation. Eur J Clin Pharmacol. 2022;78(10):1589-1600.
34. De Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart disease: Current status and perspectives (section III). position paper of the ESC working group on thrombosis–task force on anticoagulants in heart disease. Thromb Haemost. 2013;110(6):1087-1107.